Ms Anne O'Connor:

I will start on that question. As we said earlier, the focus of the audit will be in line with the Maskey report and its recommendations and in line with our expert clinical advice. We have spent a lot of time considering this. Myself and the chief clinical officer have had many meetings with clinical leaders and others in the organisation and the expert clinical advice remains that the design and scope of the audit should focus on the prescribing practice for ADHD. That is what we are focused on in terms of the use of medication. However, as I said earlier, the key challenge for us is to identify the standard criteria against which we would be carrying out that audit. That does not exist here. We cannot just pick something off a shelf and do an audit against those criteria. That work is being developed. There has been a lot of work going on to determine how that will be.

The other point that I would make, although Dr. Burke might be better qualified than me to comment on this, is that a lot of prescribing for children in respect of depression and anxiety happens through GPs in the first instance. There are many children on medication which has not been prescribed by CAMHS teams. Once we get into the broader prescribing landscape, we get into a whole range of complexities. We are starting with the ADHD audit but as that audit progresses, if flags emerge in respect of prescribing practices we will look at it in more detail.

As I also said earlier, the plans around this audit will go the national oversight group tomorrow afternoon, which is the scheduled first meeting of that group.